Neuren Pharmaceuticals Limited

Other

Auckland Uniservices Limited

Otago Innovation Limited

Curonz Holdings Company Limited

Landcare Research New Zealand Limited

Margaret Anne Brimble

Frank Sieg

Paul William Richard Harris

Jian Guan

Peter Roderick Dunbar

Geoffrey Martyn Williams

David Rennison

Peter David Gluckman

Daniel Verdon

Lesley Larsen

David Samuel Larsen

Robin Andrew James Smith

Russell James Hewitt

Morgan Jay-Smith

Morgayn Iona Read

Joanne Clare Harrison

Nathan John Stanley

Gregory Giles

Laura Molly Woods

Ivan Andrew Sammut

Jui Thiang Brian Kueh

Frank Casper Tortella

Gregory Brian Thomas

Xi-Chun May Lu

Mike John Bickerdike

Anthony Joseph Williams

Adam Heikal

Victoria Justine Muir

Douglas Wilson

Jed A Hartings

Michael Dragunow

Divina Gryder

Ashmit Kumar Anand

Thomas Hugh Wright

Norman A Abood

Brian Hopkins

Greg Murray Cook

Sergio Bova

Maurizio Cavalli

Scott Andrew Ferguson

Olivia Laita

Mary-Anne Woodnorth

Ernest Stephen Sirimanne

The invention provides novel quinoline sulfonamide compounds of Formula I: and their use for the treatment or prevention of bacterial infections caused by both Gram positive and Gram negative bacteria such as, for example, infections caused by one or more bacteria from the Enterobactericeae, Staphylococcaceae, or Streptococcaceae families. The compounds described and claimed herein may be formulated in one or more pharmaceutical or veterinary compositions for use in animal husbandry, and in particular in relation to the treatment of mastitis by directly targeting mastitis causing bacteria in a bovine herd. In certain embodiments described herein the pharmaceutical or veterinary compositions are formulated as a spray for direct administration to the udder of the bovine animal such as a cow.

Quinoline sulfonamide compounds and their use as antibacterial agents

The invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, and pharmaceutical compositions comprising the conjugates. Methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same are also contemplated.

Amino acid and peptide conjugates and conjugation process

The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to protect against ischaemic injury during a transplant event.

Carbon monoxide releasing norbornenone compounds

The present invention relates to peptides, and amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions comprising the peptides and conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the peptides and conjugates for the same, and uses of the peptides and conjugates in the manufacture of medicaments for the same.

Amino acid and peptide conjugates and uses thereof

The present invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions comprising the conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same.

Embodiments of this invention include synthetic compounds (NRP analogs) of peptides termed neural regeneration peptides (NRPs). NRP analogs are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing &#x3b2;-turns, acetylation of terminal glycine residues or by cyclization. NRP analogs can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.

Synthetic analogues of neural regeneration peptides

The present invention relates to norbormide analogs having rodenticidal activity; rodenticidal compositions comprising the analogs; uses of the analogs as rodenticides; uses of the analogs in the manufacture of rodenticidal compositions; and methods for controlling rodents using the compositions.

Rodenticidal norbormide analogues

This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function.

Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid

Embodiments of this invention provide methods for therapeutic use of cyclic G-2-allylProline (cG-2-allylP) to treat peripheral neuropathies, including toxin-induced peripheral neuropathy and diabetic peripheral neuropathy as well as manufacture of medicaments including tablets, capsules, and other orally active compositions containing cG-2-allylP, as well as injectable solutions that are useful for treatment of such conditions.

Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy

Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing &#x3b2;-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.

Neural regeneration peptide consisting of a sequence comprised in the sequence of REGRRAAPGRAGG(SEQ ID NO:1).

Neural regeneration peptides and formulations thereof

Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterized by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.

Neuroprotective bicyclic compounds and methods for their use

Embodiments of this invention provide novel peptidomimetics that contain a macrocycle, an embodiment of which is 2S,9'S,12&#x2032;S)-2-{[(1&#x2032;,4&#x2032;-Diaza-2&#x2032;-oxobicyclo[7.3.0]dodecyl)-12&#x2032;-carbonyl]amino}-1,5-pentanedioic acid trifluoroacetate. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterized by neuronal degeneration and/or neuronal cell death caused by in embodiments, toxicity or hypoxia. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.

Substituted pyrrolo[1,2-d][1,4]-diazonines and treatment of brain damage

Growing community of inventors

Auckland, New Zealand

Margaret Anne Brimble